Abstract: The morbidity of cervical cancer，endometrial cancer and ovarian cancer are increasing each year, and show younger trend. Many patients become iatrogenic menopause because of treating gynecologic cancer, show serious climacteric symptoms rapidly, and lead to lower quality of life. Menopausal hormone therapy（MHT） can control menopausal symptoms, relieve urogenital atrophy and prevent osteoporosis effectively. Studies indicate that it is relative safety for cervical squamous carcinoma，endometrial carcinoma of stage Ⅰ and ovarian epithelial carcinoma to receive MHT；ｃervical adenocarcinoma，endometrial carcinoma of stage Ⅱ and more than stage Ⅱ，granulose cell tumor of ovary and endometrial stromal sarcoma of low grade are not be suggested to receive MHT. Low dose MHT may have lighter adverse reactions while improve menopausal symptoms. The reports of the therapeutic advantages in gynecologic cancer patients increase day by day, but there have been no large-scale studies about it. In clinical usｅ，ｗe should give individual MHT combining with the situation. The application of MHT in gynecological malignant tumors is remained to be explored.

Key words: Estrogen replacement therapy, Uterine cervical neoplasms, Endometrial neoplasms, Ovarian neoplasms, Therapy, Estrogen replacement therapy, Uterine cervical neoplasms, Endometrial neoplasms, Ovarian neoplasms, Therapy